Cyclacel Pharmaceuticals
Biopharmaceutical company developing cell cycle control cancer therapies.
HQ location
Berkeley Heights, United States
Founding location
London, United Kingdom
Website
Launch date
Employees
Market cap
$7.9m
Enterprise value
$4m
Share price
$0.33 CYCC
Company register number
loading funding rounds…
Excalibur Fund Managers(exited)
Acorn Bioventures(exited)
Scottish Equity Partners(exited)
ARCH Venture Partners(exited)
Red Abbey Venture Partners(exited)
SpringRock Ventures(exited)
University of Dundee(exited)
Innovate UK(exited)
Goro Takeda(exited)
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | (90 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (6346 %) | - | - | - | - | (5954 %) | (27777 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (4859 %) | - | - | - | - | (5370 %) | (26074 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 2885 % | - | - | - | - | 4561 % | 15477 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.